Thyrocare Technologies Limited has recommended a final dividend of ₹21 per equity share for FY25, subject to approval by shareholders at the ensuing AGM. This announcement comes as the company posts a strong set of earnings for the quarter and year ended March 31, 2025.
For Q4 FY25, Thyrocare reported a 21% YoY rise in revenue from operations to ₹187.2 crore, compared to ₹154.2 crore in the same quarter last year. Gross margin improved to ₹137.7 crore, up 28% YoY, while normalized EBITDA (before ESOP) surged 78% YoY to ₹65.3 crore. Reported EBITDA came in at ₹57.4 crore, reflecting a 70% increase from Q4 FY24.
Net profit excluding exceptional items rose sharply by 88% YoY to ₹32.5 crore from ₹17.2 crore. Including exceptional items, PAT stood at ₹21.3 crore, up 24% YoY. Normalized EBITDA margin stood at 35%, while PAT margin (excl. exceptionals) was 17%.
For the full year FY25, revenue grew 20% to ₹687.3 crore and normalized EBITDA increased 37% to ₹209.9 crore. Net profit excluding exceptional items for FY25 was ₹101.2 crore, compared to ₹69.8 crore in FY24, a 45% YoY increase.
Operationally, total volume for FY25 reached 167.9 million, the company’s highest yet. Thyrocare opened new labs in Bhagalpur and Kashmir, and maintained a strong cash reserve of ₹191.8 crore as of March 2025.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
